3-FMA - PsychonautWiki
Open main menu

3-FMA

Summary sheet: 3-FMA
3-FMA
3-FMA.svg
Chemical Nomenclature
Common names 3-FMA
Substitutive name 3-Fluoromethamphetamine
Systematic name 1-(3-Fluorophenyl)-N-methylpropan-2-amine
Class Membership
Psychoactive class Stimulant
Chemical class Amphetamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 5 - 10 mg
Light 10 - 20 mg
Common 20 - 35 mg
Strong 35 - 50 mg
Heavy 50 mg +
Duration
Total 3 - 7 hours
Onset 20 - 60 minutes
Come up 30 - 60 minutes
Peak 2 - 4 hours
Offset 1 - 3 hours
After effects 6 - 12 hours



Insufflated
Dosage
Threshold < 20 mg
Light 20 - 50 mg
Common 50 - 100 mg
Strong 100 - 150 mg
Heavy 150 mg +
Duration
Total 2 - 8 hours
Onset 2 - 10 minutes
Come up 10 - 30 minutes
Peak 1 - 6 hours
Offset 1 - 2 hours
After effects 2 - 12 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Alcohol
GHB
GBL
Opioids
Cocaine
Caffeine
Ketamine
Methoxetamine
Psychedelics
ArrayC-x
Cannabis
DMT
LSD
Mescaline
Psilocybin mushrooms
DXM
PCP
Array5x-NBOMe
ArrayC-T-x
5-MeO-xxT
DOx
Tramadol
aMT
MAOIs


3-Fluoromethamphetamine (also known as 3-FMA) is a novel synthetic ring-substituted fluorinated amphetamine compound that produces entactogenic and stimulant effects when administered. Following the introduction of 3-FEA, 3-FMA subsequently entered the designer drug market as a compound structurally related to a series of fluorinated substituted amphetamines that originally included compounds such as 2-FMA, 3-FA, 4-FMA, 4-FA.[1]

Like its parent compound 3-FA, the pharmacological, toxicological, and subjective effects of 3-FMA in humans have yet to be mapped out in detail. Early reports have so far characterized 3-FMA as a moderately potent serotonin-dominant triple monoamine releaser (or reuptake inhibitor) that produces a relatively short-lived balance of entactogenic and stimulant effects.[citation needed] Based on related compounds, it is not unreasonable to speculate that this compound possesses neurotoxic, cardiotoxic and other potential to-be-discovered toxic properties[citation needed], which is why extreme caution is advised.

3-FMA has an extremely short history of recreational use and has yet to be documented being sold on the streets. It has recently been made available for sale on the gray market as a research chemical through online vendors. The appearance of it as well as 3-FEA on the research chemicals market coincides with the increased efforts to control the popular entactogenic stimulant 4-FA.[citation needed]

Due to its potent psychostimulant effect, likely habit-forming properties as well as unknown toxicity profile, it is strongly recommended that one use proper harm reduction practices if choosing to use this substance.

Contents

Chemistry

3-FMA, or 3-fluoromethamphetamine, is a synthetic molecule of the amphetamine family. Molecules of the amphetamine family contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an methyl chain with an additional methyl substitution at Rα (i.e. amphetamines are alpha-methylated phenethylamines). 3-FMA is the 3-position fluorinated analog methamphetamine; however, it is currently speculated to behave more in the manner of shorter-lived entactogenic stimulant. Additionally, is is also a positional isomer of 2-FMA and 4-FMA.

Pharmacology

 

This pharmacology section is incomplete.

You can help by adding to it.

Although 3-FMA has not been formally studied on the same level as traditional amphetamines, it is currently assumed that like other substituted amphetamines with substitutions at similar positions, it most likely acts primarily as a triple releasing agent of serotonin, dopamine, and norepinephrine.[citation needed]

Subjective effects

 
 This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below are cited from the subjective effect index, which is based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy degree of skepticism. It is worth noting that these effects will rarely (if ever) occur all at once, although higher doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death. Early reports suggest 3-FMA has an effect profile that lies in between that of 4-FMA and 2-FMA, possessing both the functional properties of 2-FMA and the euphoric properties of 4-FMA. At lower doses, it has been reported to lean towards functional and productive use, while as one increases the dose, the euphoria becomes both more prevalent as well as distracting.[citation needed]


Physical effects
 

After effects
 

Cognitive effects
 


Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Toxicity and harm potential

Further information: Research chemicals § Toxicity and harm potential
 

This toxicity and harm potential section is a stub.

As such, it may contain incomplete or even dangerously wrong information. You can help by expanding or correcting it.
We also recommend that you conduct independent research and use harm reduction practices when using this substance.

The toxicity and long-term health effects of human recreational 3-FMA use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-FMA has an extremely short history of human usage, becoming available only in mid-2017. Anecdotal evidence from people who have tried 3-FMA within the community suggests that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

Due to its putative serotonin-releasing and entactogenic properties, it is possible that 3-FMA may display excess activity at the 5-HT2b receptor, which, would make it cardiotoxic with long-term use as seen in other 5-HT2b agonists such as fenfluramine and MDMA.[citation needed]

It is perhaps worth noting that in the field of medicinal chemistry, the fluorine substitution is sometimes seen as desirable in central nervous system pharmaceutical agents, and is a common practice due to the corresponding increase in lipophilicity granted by the substitute.[2]

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

Although it still remains to be seen, the chronic use of 3-FMA likely can be considered moderately addictive with a high potential for abuse and capable of causing psychological dependence among a certain population of users. When dependence or addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 3-FMA develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 10 days to be back at baseline (in the absence of further consumption). 3-FMA presents cross-tolerance with all dopaminergic and serotonergic stimulants and entactogens, meaning that after the consumption of 3-FMA all stimulants will have a reduced effect (including atypical stimulants one might not expect, like MDMA or amphetamine due to its reliance on dopamine and norepinephrine to exert its full euphoric effect).

Psychosis

Main article: Stimulant psychosis

Abuse of compounds within the amphetamine chemical class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions).[3] A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[4][5] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[6] Psychosis very rarely arises from therapeutic use.[7][8]

Dangerous interactions

Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when taken with other substances. The following lists some known dangerous combinations, but cannot be guaranteed to include all of them. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.

  • Alcohol - Drinking alcohol on stimulants is considered risky because it reduces the sedative effects of the alcohol that the body uses to gauge drunkenness. This often leads to excessive drinking with greatly reduced inhibitions, increasing the risk of liver damage and increased dehydration. The effects of stimulants will also allow one to drink past a point where they might normally pass out, increasing the risk. If you do decide to do this then you should set a limit of how much you will drink each hour and stick to it, bearing in mind that you will feel the alcohol and the stimulant less.
  • GHB/GBL - Stimulants increase respiration rate allowing a higher dose of sedatives. If the stimulant wears off first then the opiate may overcome the user and cause respiratory arrest.
  • Opioids - Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
  • Cocaine - This combination of stimulants will increase strain on the heart. It is not favored as cocaine has a mild blocking effect on dopamine releasers like amphetamine.
  • Caffeine - This combination of stimulants is generally considered unnecessary and may increase strain on the heart, as well as potentially causing anxiety and physical discomfort.
  • Tramadol - Tramadol and stimulants both increase the risk of seizures.
  • DXM - Both substances raise heart rate, in extreme cases, panic attacks caused by these substances have led to more serious heart issues.
  • Ketamine - No unexpected interactions. Likely to increase blood pressure but not an issue with sensible doses. Moving around on high doses of this combination may be ill advised due to risk of physical injury.
  • PCP - Increases risk of tachycardia, hypertension, and manic states.
  • Methoxetamine - Increases risk of tachycardia, hypertension, and manic states.
  • Psychedelics - Increases risk of anxiety, paranoia, and thought loops.
    • 25x-NBOMe - Amphetamines and NBOMes both provide considerable stimulation that when combined they can result in tachycardia, hypertension, vasoconstriction and, in extreme cases, heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
    • 2C-x
      • 2C-T-x
    • 5-MeO-xxT
    • aMT
    • Cannabis - Stimulants increase anxiety levels and the risk of thought loops and paranoia which can lead to negative experiences.
    • DMT
    • DOx
    • LSD
    • Mescaline
    • Psilocybin mushrooms
  • MAOIs - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably. MAO-A inhibitors with amphetamine can lead to hypertensive crises.

Legal issues

 

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

3-FMA is currently a grey area compound within many parts of the world. However, people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.

  • Canada: 3-FMA would be considered Schedule I as it is an analogue of Amphetamine.[9]
  • China: As of October 2015 3-FMA is a controlled substance in China.[10]
  • Germany: 3-FMA is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[11] as of December 13, 2014.[12] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[13]
  • New Zealand: 3-FMA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.[14]
  • United Kingdom: 3-FMA is considered a Class A drug as a result of the amphetamine analog clause of the Misuse of Drugs Act 1971.[15]
  • United States: 3-FMA may be considered an analogue of amphetamine under the Federal Analogue Act. The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act, allowing any chemical "substantially similar" to an illegal drug (in Schedule I or II) to be treated as if it were also in Schedule I or II, but only if it is intended for human consumption.[citation needed]

See also

External links

References

  1. ↑ Quednow, B., Girreser, U., Junge, T., & Ro, P. (2005). Isomeric Fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs), 148, 143–156. https://doi.org/10.1016/j.forsciint.2004.05.003
  2. ↑ Fluorine substituent effects (on bioactivity) | http://www.sciencedirect.com/science/article/pii/S002211390100375X
  3. ↑ Treatment for amphetamine psychosis | [1]
  4. ↑ Treatment for amphetamine psychosis | [2]
  5. ↑ Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
  6. ↑ Treatment for amphetamine psychosis | [3]
  7. ↑ Stimulant Misuse: Strategies to Manage a Growing Problem | http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf
  8. ↑ http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf
  9. ↑ Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
  10. ↑ 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html
  11. ↑ "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 19, 2019. 
  12. ↑ "Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (in German). Bundesanzeiger Verlag. Retrieved December 19, 2019. 
  13. ↑ "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 19, 2019. 
  14. ↑ http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576
  15. ↑ Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I
Retrieved from ‘https://psychonautwiki.org/w/index.php?title=3-FMA&oldid=138685’